|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-3-4
|
|
pubmed:abstractText |
Debio-025 is an oral cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus activity in vitro. Its effect on viral load as well as its influence on intracellular Cyp levels was investigated in a randomized, double-blind, placebo-controlled study. Mean hepatitis C viral load decreased significantly by 3.6 log(10) after a 14-day oral treatment with 1200 mg twice daily (P < 0.0001) with an effect against the 3 genotypes (1, 3, and 4) represented in the study. In addition, the absence of viral rebound during treatment indicates that Debio-025 has a high barrier for the selection of resistance. In Debio-025-treated patients, cyclophilin B (CypB) levels in peripheral blood mononuclear cells decreased from 67 +/- 6 (standard error) ng/mg protein (baseline) to 5 +/- 1 ng/mg protein at day 15 (P < 0.01). CONCLUSION: Debio-025 induced a strong drop in CypB levels, coinciding with the decrease in hepatitis C viral load. These are the first preliminary human data supporting the hypothesis that CypB may play an important role in hepatitis C virus replication and that Cyp inhibition is a valid target for the development of anti-hepatitis C drugs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1527-3350
|
|
pubmed:author |
pubmed-author:AeschlimannChristianC,
pubmed-author:BobardtMichaelM,
pubmed-author:CielniakIwonaI,
pubmed-author:CrabbéRafR,
pubmed-author:DumontJean-MauriceJM,
pubmed-author:FlisiakRobertR,
pubmed-author:GallayPhilippeP,
pubmed-author:GrosgurinPierreP,
pubmed-author:HigersbergerJozefJ,
pubmed-author:HorbanAndrzejA,
pubmed-author:KierkusJarekJ,
pubmed-author:Nicolas-MétralValérieV,
pubmed-author:PorchetHervéH,
pubmed-author:ScalfaroPietroP,
pubmed-author:SelvarajahSuganyaS,
pubmed-author:SiwakEwaE,
pubmed-author:Wiercinska-DrapaloAlicjaA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
817-26
|
|
pubmed:meshHeading |
pubmed-meshheading:18302285-Administration, Oral,
pubmed-meshheading:18302285-Adult,
pubmed-meshheading:18302285-Aged,
pubmed-meshheading:18302285-Antiviral Agents,
pubmed-meshheading:18302285-Cyclophilin A,
pubmed-meshheading:18302285-Cyclophilins,
pubmed-meshheading:18302285-Cyclosporine,
pubmed-meshheading:18302285-Double-Blind Method,
pubmed-meshheading:18302285-Drug Resistance, Viral,
pubmed-meshheading:18302285-Female,
pubmed-meshheading:18302285-HIV Infections,
pubmed-meshheading:18302285-HIV-1,
pubmed-meshheading:18302285-Hepacivirus,
pubmed-meshheading:18302285-Hepatitis C,
pubmed-meshheading:18302285-Humans,
pubmed-meshheading:18302285-Male,
pubmed-meshheading:18302285-Middle Aged,
pubmed-meshheading:18302285-Peptidylprolyl Isomerase,
pubmed-meshheading:18302285-Placebos,
pubmed-meshheading:18302285-Virus Replication
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.
|
|
pubmed:affiliation |
Department of Infectious Diseases, Medical University of Bialystok, Bialystok, Poland.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
